| Objective To evaluate the clinical efficacy of 99Tc-MDP in the treatment of rheumatoid arthritis patients with osteoporosis. Methods 49 inpatients who were treated with 99Tc-MDP and 30 outpatients were selected and followed up for one year, and collected the clinical data. Results There were no significant differences in the baseline clinical data of the two groups of patients with age, course of disease, BMI, morning stiffness time, VAS, ESR, CRP, RF, bone mineral density, the number of joint swelling and tenderness (P >0.05). The clinical indicators of patients in the study group treated with 99Tc-MDP were lower than those in the control group after one year of treatment (P <0.05). The bone mineral density of the study group had improved after 12 months of 99Tc-MDP treatment (P <0.05), while the control group had no significant difference in lumbar spine and femoral neck BMD before and after treatment (P >0.05). Conclusion 99Tc-MDP can relieve inflammatory and increase bone mineral density in in the treatment of rheumatoid arthritis patients with osteoporosis. |